What is Trace Biosciences?
Trace Biosciences operates at the intersection of surgical oncology and molecular diagnostics. The company specializes in the development of fluorescence-based imaging agents that provide surgeons with real-time, high-resolution visualization of peripheral nerves. This technological capability addresses a critical unmet need in the operating room, where the preservation of nerve integrity is paramount to patient recovery and long-term quality of life. By integrating these diagnostic agents into standard surgical workflows, Trace Biosciences is establishing a new standard of care that prioritizes safety and procedural accuracy. The firm's current lifecycle stage, characterized by major enterprise-level funding, underscores its transition from early-stage research to a more robust clinical development phase, supported by strategic collaborations with leading healthcare institutions.
How much funding has Trace Biosciences raised?
Trace Biosciences has raised a total of $8.3M across 1 funding round:
Stock/Share Issuance
$8.3M
Stock/Share Issuance (2026): $8.3M, investors not publicly disclosed
Key Investors in Trace Biosciences
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Trace Biosciences?
With the recent influx of capital, Trace Biosciences is expected to prioritize the expansion of its clinical research pipeline and the scaling of its diagnostic agent manufacturing capabilities. The strategic roadmap likely includes accelerating regulatory milestones and deepening partnerships with major surgical centers to validate the efficacy of its imaging technology in diverse clinical environments. As the company moves toward commercialization, the focus will shift from preclinical validation to large-scale clinical trials, aiming to demonstrate the long-term economic and clinical benefits of nerve-sparing surgical techniques. This growth trajectory positions the firm as a high-value player in the medical technology sector, with potential for significant disruption in the surgical imaging market.
See full Trace Biosciences company page